Alliances
Beigene and Novartis announced the FDA has deferred action on the BLA for tislelizumab until inspections of facilities in China can be completed.
Regeneron Pharmaceuticals and Sanofi announced positive results from a Phase III trial of Dupixent (dupilumab) in kids ages one to 11 years with eosinophilic esophagitis (EoE).
The agreement with Merck brings $290 million upfront to Orion to access the latter’s investigational candidate, ODM-208, for mCPRC and other related drugs.
Gossamer Bio sold shares of its common stock to pave its runway through mid-2024 while Teva and AbbVie reach deals in opioid settlements.
In what seems like an unlikely collaboration, Seattle-based Fred Hutchinson Cancer Center (Fred Hutch) is partnering with Amazon to develop cancer vaccines.
Backed by biopharma royalty, Areteia Therapeutics will focus on developing an old molecule for a very prevalent disease - asthma.
Genentech has exercised the second option in its potentially $1.7 billion agreement with Bicycle Therapeutics, triggering a $10 million payment.
The experimental drug, being developed to treat immunoglobulin A nephropathy, is IONIS-FB-L Rx, which hit the mark in a Phase II study showing a change in urinary protein after 29 weeks of treatment.
Sanofi announced positive data for its therapeutic, fitusiran, for treating patients with hemophilia A and B, as well as efanesoctocog alfa therapy for treating hemophilia A.
In a filing with the SEC, Abbvie’s decision to terminate came after the two firms jointly conducted a review of their next steps for the drug.
PRESS RELEASES